Celgene Corporation (NASDAQ:CELG) today announced the appointment of Jennifer Dudinak, Pharm.D., as Senior Vice President, Global Regulatory Affairs, reporting to Jay Backstrom, M.D., Chief Medical Officer, effective April 30, 2018. Jennifer will be responsible for regulatory strategy and execution across Celgene’s portfolio and will serve on the company’s Executive Committee.
“Jennifer possesses deep regulatory expertise and has a proven record of leading highly-effective cross-functional teams,” said Jay Backstrom, M.D., Chief Medical Officer of Celgene Corporation. “Jennifer will lead the regulatory strategy at all stages of our pipeline, which is essential to accelerate and expand our portfolio.”
“Strengthening our Regulatory Affairs team is critical to our future success and is a top corporate objective at this stage of Celgene’s growth,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene Corporation. “Jennifer is an outstanding addition to Jay’s global leadership team and the Executive Committee.”
Jennifer has more than 20 years of regulatory experience, integrating regulatory strategy into drug development and precision medicine across multiple therapeutic areas. She joins Celgene from GlaxoSmithKline (GSK), where she was Vice President and Head of Regulatory Affairs for the Pharma Therapeutic Team. Also at GSK, she served as Vice President of Global Regulatory Affairs for Oncology, in addition to providing regulatory leadership on a number of innovation and operational excellence initiatives. Prior to joining GSK, Jennifer served as Global Head of Regulatory Affairs for Inflammation, Virology and Ophthalmology and Therapeutic Group Head of Regulatory Affairs for Oncology at Genentech/Hoffman-La Roche, where she completed her Pharmacy Post-Doctoral Fellowship. Jennifer received her Doctor of Pharmacy and Bachelor of Science in Pharmacy from Rutgers University.